Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia

1 Jul 2021

Abstract excerpt

Abstract To understand mechanisms of response to BET inhibitors (BETi), we mined the Beat AML functional genomic data set and performed genome-wide CRISPR screens on BETi-sensitive and BETi-resistant acute myeloid leukemia (AML) cells. Both strategies revealed regulators of monocytic differentiation—SPI1, JUNB, FOS, and aryl-hydrocarbon receptor signaling (AHR/ARNT)—as determinants of BETi response. AHR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34568834
DOI: 10.1158/2643-3230.bcd-21-0012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid LeukemiaPMID 34568834Read ↗

PU.1 inhibition sensitizes stem-monocytic AML to BCL2 blockadeSemantic proximity Read ↗

Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells.Semantic proximity Read ↗

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid LeukemiaSemantic proximity Read ↗

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapySemantic proximity Read ↗

RAS pathway activation drives clonal selection and monocytic differentiation in FLT3 and BCL2 inhibitor resistanceSemantic proximity Read ↗

Heme-Sensing Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-MimeticsSemantic proximity Read ↗

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML CellsSemantic proximity Read ↗

Venetoclax Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AMLSemantic proximity Read ↗

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated ApoptosisSemantic proximity Read ↗

A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapySemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.